SEVELAMER CARBONATE

Post-LOE

sevelamer carbonate

ANDAORALTABLET
Approved
Oct 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
9

Clinical Trials (5)

NCT02332811Phase 3Completed

An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients

Started Oct 2013
96 enrolled
Renal Failure Chronic
NCT01574326Phase 2Completed

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Started May 2012
101 enrolled
HyperphosphatemiaChronic Kidney Disease
NCT01736150Phase 3Completed

Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis

Started Mar 2010
205 enrolled
Chronic Kidney DiseaseChronic Kidney Disease on Hemodialysis
NCT00853242Phase 2Completed

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Started Feb 2009
349 enrolled
Kidney Failure, Chronic
NCT00833768Phase 3Terminated

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis

Started Jan 2009
5 enrolled
Chronic Kidney DiseaseHyperphosphatemia